Pricing Log in Create free account
Saturday 17 October 2026 Export SER’s income statement to Excel — free account

Serina Therapeutics, Inc.

SER Healthcare Biotechnology

In the quarter to June 2026, revenue grew 2,500.0%, EPS grew 16.7% and free cash flow fell 76.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.77 0.02 −1.12%
Market cap
$45.5M
P/E
0.0×
Fwd P/E
−1.0×
Dividend yield
—
F-score
2/9
Altman Z
−22.07
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.08
Total sells 0.41
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 3 1 1 — — —
Sell 6 7 5 1 2 — — — — — — —
Insider Ownership 24.32%

Capital & Financial Ratios $m

Market Cap 45.46
Revenue 0.18
Net Income (21.18)
Free Cash Flow (21.20)
Net Debt (19.94)
Current Ratio 6.65 (at or above 1.5: strong)
Debt/Equity 0.16 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (1.02) (negative: loss-making)
P/S ratio 160.23 (above 10: high)
P/B ratio 1.55
Past 5Y EPS Growth —
This Y EPS Growth 17.35% (at or above 15%: strong)
Next Y EPS Growth 26.95% (at or above 15%: strong)
Next Y revenue growth 0.00%
Next 5Y EPS Growth 18.02% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 66.0×, against a ten-year median of 152×; over the ten years it ranged from 6.6× in 2024 to 1,889× in 2023.
P/S against its own 10 years 51.53%
10-year low 10-year high
EV/Sales against its own 10 years 31.65%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2016 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 8 4 3 23
Receivables — — — —
Inventory — — — —
Other — — — —
8 6 6 25
2023 2024 2025 Q'26
Payables 1 1 2 2
ST’ Debt — — — —
Other 0 0 0 1
1 2 4 4

Compound Annual Growth %

10y 5y 3y
Sales — (18.48%) 56.37%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 — 0 — — 0
’24 0 0 0 0 0
’23 0 0 0 3 3
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (7) — — —
’25 (4) (4) (4) (6) (18)
’24 (2) (8) (3) (5) (17)
’23 (1) (1) (1) 0 (2)
’22 (2) (2) (1) (1) (6)
’21 (3) (2) (2) (2) (8)
’20 (2) (2) (2) (2) (8)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (5) (7) — — —
’25 (4) (4) (4) (6) (18)
’24 (2) (8) (3) (5) (17)
’23 (1) (1) (1) 0 (3)
’22 (2) (2) (1) (1) (6)
’21 (3) (2) (2) (2) (8)
’20 (2) (2) (2) (2) (8)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.58) (0.55) — — —
’25 (0.49) (0.66) (0.45) (0.31) (1.91)
’24 (5.38) 0.51 0.13 (0.27) (1.51)
’23 0.19 0.11 0.23 0.18 0.72
’22 (2.46) (2.46) (2.11) (2.46) (9.86)
’21 (2.11) (2.46) (1.76) (2.00) (8.10)
’20 (2.82) (2.46) (2.46) (2.46) (10.21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — 40.36 41.43 23.79 18.43 17.86 11.79 3.81 1.71

Analyst estimates 2026–2028

Powerpack
High — — 212.50 182.14 140.36 109.29 47.50 35.71 23.18 7.92
People
People Employees — 17 12 17 11 10 9 8 13 16
Revenue/emp, $m 0.00 0.08 0.12 0.10 0.03 0.01 0.00 0.39 0.00 0.01
Income, $m
Income, $m Revenue 2 1 1 2 0 0 0 3 0 0
Gross margin, % 45.32 88.03 73.93 85.88 92.80 86.81 61.76 100.00 100.00 100.00
EBT (17) (7) (8) (12) (11) (9) (11) 5 (11) (19)
EBT margin, % (1,041.72) (472.72) (553.80) (708.10) (3,081.99) (5,959.72) (30,947.06) 167.11 (20,012.50) (14,766.92)
Net income (15) (7) (8) (12) (10) (9) (10) 5 (11) (19)
Depreciation 1 1 1 1 2 1 3 0 1 0
Per share, $
Per share, $ Revenue 0.05 1.61 1.41 1.63 0.34 0.13 0.03 1.41 0.01 0.01
Earnings (0.43) (7.63) (7.39) (11.62) (10.21) (8.10) (9.86) 2.36 (1.51) (1.91)
Cash flow (0.24) (7.22) (8.06) (9.60) (7.31) (7.30) (5.50) (1.11) (2.33) (1.76)
Capex 0.00 0.00 (0.02) (0.61) (0.02) 0.00 0.00 (0.23) 0.00 (0.01)
Free cash flow (0.24) (7.22) (8.08) (10.20) (7.33) (7.30) (5.50) (1.33) (2.33) (1.77)
Book value (0.65) 9.56 8.30 2.47 (5.04) (11.04) (16.05) (14.45) 0.07 0.00
Shares, m 36 1 1 1 1 1 1 2 7 10
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.35 0.00 0.00
P/S 0.00 0.00 77.84 39.82 160.88 290.89 633.44 10.60 658.37 107.53
P/B 11.83 11.83 13.20 26.29 0.00 0.00 0.00 0.00 72.58 0.00
EV/Sales 0.00 0.00 73.04 39.59 176.87 378.52 1,147.52 9.62 673.33 122.88
EV/FCF 0.00 (7.43) (12.72) (6.33) (8.15) (6.92) (6.55) (10.18) (2.20) (1.23)
Cash, $m
Cash, $m Operating cash flow (8) (6) (8) (10) (8) (8) (6) (2) (17) (18)
Capex 0 0 0 (1) 0 — — (1) 0 0
Free cash flow (8) (6) (8) (11) (8) (8) (6) (3) (17) (18)
Balance, $m
Balance, $m Working capital (25) 6 5 1 (3) (7) (8) 6 3 3
Total debt — — — 2 4 6 10 3 — 3
Net debt 0 (7) (7) (1) 3 5 10 (5) (4) 0
Shareholders’ equity (23) 8 8 3 (5) (12) (17) (32) 1 0
Returns, %
Returns, % ROA (241.05) (102.38) (73.90) (134.20) (191.17) (245.09) (327.19) 86.31 (142.00) (280.54)
ROIC 0.00 (441.14) (461.16) (437.78) 0.00 0.00 0.00 0.00 0.00 0.00
ROE 191.98 87.15 (90.66) (224.08) 781.94 100.46 71.68 (21.24) 70.10 858.45
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025

Charts ten years each

Serina Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
KLRS Kalaris Therapeutics Inc. $47.8M — (loss-making) — — n/m +11.91% (above 0%: growing) 0.00% 0.00% Compare
IBIO iBio, Inc. $47.6M — (loss-making) — (loss-making) +100.00% (above 0%: growing) n/m −35.33% (below 0%: shrinking) 100.00% 0.00% Compare
CLNN Clene Inc. $47.0M — (loss-making) — (loss-making) +233.33% (above 0%: growing) n/m +45.43% (above 0%: growing) 60.00% (5,941.11%) Compare
TVGN Tevogen Inc. $46.1M — (loss-making) — — n/m +5.78% (above 0%: growing) — 0.00% Compare
INMB INmune Bio, Inc. $45.8M — (loss-making) — (loss-making) +8.70% (above 0%: growing) n/m +55.39% (above 0%: growing) 100.00% 0.00% Compare
IMA ImageneBio, Inc. $45.7M — (loss-making) — (loss-making) −60.08% (below 0%: shrinking) n/m +23.76% (above 0%: growing) 100.00% 0.00% Compare
SER Serina Therapeutics, Inc. $45.5M — (loss-making) — (loss-making) +2,500.00% (above 0%: growing) n/m −76.82% (below 0%: shrinking) 100.00% 0.00%
ANVS Annovis Bio, Inc. $44.8M — (loss-making) — — n/m −329.18% (below 0%: shrinking) — 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $44.5M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $46.0M — — +54.35% — +17.84% 80.00% 0.00%

All 614 Biotechnology stocks →

Serina Therapeutics, Inc. (SER) key facts

  • Serina Therapeutics, Inc. (SER) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
  • As of October 16, 2026, SER traded at $1.77, a market capitalization of $45.5 million.
  • Return on equity was 858.5% and debt-to-equity 0.16.
  • Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −22.07 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Serina Therapeutics, Inc. (SER) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SER · Data as of Jun 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com